The encouraging safety and efficacy profile of PD-1 inhibitors in relapsed and refractory HL raises interest in using PD-1 inhibitors earlier in HL treatment and in combination with other therapies. The gene discussed is PDCD1; the disease is Hodgkins lymphoma.